There are several reasons that TB patients don’t or can’t adhere to their treatment.
The overcrowded conditions of prisons make them a high-risk environment for the spread of infectious diseases such as TB.
Beitbridge and Musina are two border towns in Zimbabwe and South Africa that see many migrants pass through – with different health needs.
To understand the perceptions of TB patients about their quality of life, it’s useful to have a comparison with “apparently healthy” people.
As antibiotics lose their power to treat some forms of TB, interest in the antibacterial powers of curdlan is rising.
We expected to find that screening everybody for TB would identify individuals not yet diagnosed, and treating them quickly would reduce the prevalence of TB in the community.
India’s recent Tuberculosis survey showed worse results than expected.
In high-income countries people at high risk of TB disease undergo screening programmes even when they have no symptoms.
In 2020 TB case detection fell by almost 20% and mortality rose for the first time in a decade. These setbacks are directly attributable to the COVID-19 pandemic.
Manufacturers and health systems have shown that vaccines can be quickly and effectively deployed when accompanied by keen political and financial commitments.
As a disease progresses, so too must the underlying data and reporting improve to manage the progression of the outbreak.
This challenges the current assumption that coughing is the primary driver of TB transmission.
Progress against tuberculosis has long been inadequate to reach the target of elimination by 2030. But before the COVID-19 pandemic the world was making steady progress in diagnosing and treating TB.
Smallpox, tuberculosis, measles, syphilis … a new book describes how recurring epidemics nearly wiped out Australia’s First Peoples.
COVID has shown us we can develop a range of safe and effective vaccines. Now we need to do the same for TB.
BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
South Africa needs a public health response that expands the successes of the country’s HIV testing and treatment programme to provide care for multiple diseases.
Not achieving the targets for children and adolescents in sub-Saharan Africa means that new infections will continue to increase and HIV related mortality will be a reality for decades to come.
The key actions needed to end AIDS are relatively clear. The question is whether every government, funder, and implementing organisations will apply them.
Until vaccines that are capable of protecting all populations against TB are developed, treatment is the best option to preventing infection.